NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: ZePeptide

Published 12 Nov 2026. 36-page investigative report on who is behind ZePeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 103 Finnrick lab tests, ZePeptide's overall pass rate is 61% (63 pass / 39 fail). The catalog is uneven rather than uniformly bad: GHK-Cu and Tirzepatide are the stronger relative choices, while NAD+ and Wolverine are the clearest avoid-or-upgrade signals. The full report shows how ratings compress under stricter purity and fill assumptions.

The non-lab risk is authentication. The current zepeptides.org storefront was registered in October 2026 and says there is no second official domain, yet linked ZePeptide and sister surfaces share analytics, templates, pricing and enterprise blocks while making conflicting official-domain and COA-site claims. The old .com is third-party parking and the .us node was dead at capture.

The corporate story also splits. Public materials point to a historical Shijiazhuang Zetai anchor, a current Nanjing Peptide self-attribution that was not corroborated on Nanjing's own site, and QIN BGLITAI press and link-builder assets left on the live ZePeptide site. The full report lays out which records support each layer and which links remain unproved.

ZePeptide publishes a large certificate gallery, but the lot-to-order chain is weak: captured COAs use Gmail or URL client/manufacturer fields, dead or sister domains, and one NAD+ document shows a PRISM AMINO vial. Named scientific and QA personas remain publicly unverified; payment rails are crypto/bank-first with no public beneficiary.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 11 tested products
  • Domain migration timeline and infrastructure comparison across ZePeptide, Zeniviapep, HK Peptides and Vitalis surfaces
  • Corporate identity analysis covering Zetai, Nanjing Peptide and QIN BGLITAI artifacts
  • COA chain-of-custody review for Janoshik, Freedom, Vanguard and TSurgeX documents
  • Payment, fulfilment and buyer-verification checklist, including beneficiary and channel-authentication prompts
  • Exhibit index with RDAP captures, storefront screenshots and certificate images

Risk assessment

  • Identity transparency and ultimate-control opacity — high: Nanjing self-attribution remains unverified; historical Zetai anchor exists; no ZePeptide UBO, payment beneficiary or public business-license verification was established.
  • Brand-authentication and copycat/channel-confusion risk — high: zepeptides.org claims no second official domain while zeniviapep.com, hkpeptides.us and zepeptide.co present conflicting ZePeptide channels; zepeptide.us is dead and zepeptide.com is third-party parking.
  • Lot/COA traceability and manufacturer-of-record mismatch — high: No public lot-to-order lookup; COAs name Gmail/web URLs and dead or sister domains as manufacturer fields, with PRISM AMINO and TSurgeX documents pointing to white-label or bulk-supply layers.
  • Irreversible payment and fulfilment-loss exposure — high: Linked sites list crypto and bank-transfer rails without a buyer-protected option; beneficiary is unpublished and buyer reports of repeat-payment pressure or silence are unadjudicated.
  • Unverified GMP/ISO/own-facility claim risk — high: No public GMP or ISO certificate number, facility audit, inspection record or release table; 99.5% purity badge has no stated basis and own-facility COA claims conflict with third-party documents.
  • Operational continuity and domain-churn risk — high: Historical zepeptide.com was lost to a third party, zepeptide.us is dead, zepeptides.org was registered in October 2026, legacy nodes are degraded and zepeptides.com is password-gated.
  • Product-specific quality risk: NAD+, Wolverine, MOTS-c, TB-500 — high: Finnrick: NAD+ 20% (0/3), Wolverine 20.33% (0/3), MOTS-c 33.76% (1/3), TB-500 44.75% (4/7).
  • Product-specific quality caution: BPC-157, Ipamorelin, Retatrutide, Tesamorelin — medium: Finnrick: BPC-157 51.7% (6/11), Ipamorelin 61% (1/3), Retatrutide 66.59% (28/42 with 14 fail), Tesamorelin 62.43% (7/8).
  • Affiliate-promotion disclosure risk — medium: First-party 5% referral commission and 5% invitee discount are disclosed on the vendor page; no external paid promoter was captured, but testimonials or codes need disclosure scrutiny.